Journal ArticleDOI
Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.
Ana Paula Fernandes,Eduardo A.F. Coelho,George Luiz Lins Machado-Coelho,Gabriel Grimaldi,Ricardo T. Gazzinelli,Ricardo T. Gazzinelli,Ricardo T. Gazzinelli +6 more
Reads0
Chats0
TLDR
An amastigote specific antigen (A2) is identified that contains an immunogenic epitope for CD4+ T helper (Th) cells and multiple repetitive units encoding CD8+ cytotoxic T lymphocyte (CTL) epitopes that improve the level of vaccine-induced cell-mediated immunity and protection against visceral leishmaniasis.About:
This article is published in Current Opinion in Microbiology.The article was published on 2012-08-01. It has received 71 citations till now. The article focuses on the topics: Visceral leishmaniasis & Amastigote.read more
Citations
More filters
Journal ArticleDOI
Determinants for the Development of Visceral Leishmaniasis Disease
TL;DR: This review discusses the vector, host, and pathogen factors that mediate the development of visceral leishmaniasis and examines the progression of the parasite from the initial site of sand fly bite to the visceral organs and its ability to survive there.
Journal ArticleDOI
Vaccines for visceral leishmaniasis: A review.
Keerti Jain,N. K. Jain +1 more
TL;DR: Visceral leishmaniasis is one of the most severely neglected tropical diseases recognized by the World Health Organization and few vaccines including Leishmune®, Leishtec, and CaniLeish® have been licensed for canine visceral leish maniasis.
Journal ArticleDOI
Antigenicity and Protective Efficacy of a Leishmania Amastigote-specific Protein, Member of the Super-oxygenase Family, against Visceral Leishmaniasis
Vívian T. Martins,Miguel A. Chávez-Fumagalli,Lourena E. Costa,Adriana Monte Cassiano Canavaci Martins,Paula S. Lage,Daniela P. Lage,Mariana C. Duarte,Diogo G. Valadares,Rubens Daniel Miserani Magalhães,Tatiana G. Ribeiro,Ronaldo Alves Pinto Nagem,Wanderson D. DaRocha,Wiliam César Bento Régis,Manuel Soto,Eduardo A.F. Coelho,Ana Paula Fernandes,Carlos Alberto Pereira Tavares +16 more
TL;DR: It is shown that this Leishmania oxygenase amastigote-specific protein can be used for a more sensitive and specific serodiagnosis of asymptomatic and symptomatic CVL and, when combined with a Th1-type adjuvant, can also be employ as a candidate antigen to develop vaccines against VL.
Journal ArticleDOI
Current status on prevention and treatment of canine leishmaniasis.
Rosa M. Reguera,Miguel Ángel Olego Morán,Yolanda Pérez-Pertejo,Carlos García-Estrada,Rafael Balaña-Fouce +4 more
TL;DR: This review highlights the current use of preventive and eradicative weapons to fight against this disease, which is a scourge for dogs and a continuous threat to human beings.
Journal ArticleDOI
The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later.
Virginie Martin,Ioannis Vouldoukis,Javier Moreno,David McGahie,Sylvie Gueguen,Anne-Marie Cuisinier +5 more
TL;DR: Vaccinated dogs retained significantly stronger cell-mediated immune responses against the parasite despite a virulent challenge and had significantly lower mean parasite burdens at the end of the study, associated with a lower probability of developing active infections.
References
More filters
Journal ArticleDOI
Toll-like receptor control of the adaptive immune responses.
Akiko Iwasaki,Ruslan Medzhitov +1 more
TL;DR: Recognition of microbial infection and initiation of host defense responses is controlled by multiple mechanisms and recent studies have provided important clues about the mechanisms of TLR-mediated control of adaptive immunity orchestrated by dendritic cell populations in distinct anatomical locations.
Journal ArticleDOI
Leishmaniasis: current situation and new perspectives.
TL;DR: Research for leishmaniasis has been more and more focusing on the development of new tools such as diagnostic tests, drugs and vaccines, and the newly available control tools should allow a scaling up of control activities in priority areas.
Journal ArticleDOI
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.
Patricia A. Darrah,Dipti T. Patel,Paula M De Luca,Ross W. B. Lindsay,Dylan F. Davey,Barbara J. Flynn,Søren T. Hoff,Peter Andersen,Steven G. Reed,Sheldon L. Morris,Mario Roederer,Robert A. Seder +11 more
TL;DR: The quality of a CD4+ T-cell cytokine response can be a crucial determinant in whether a vaccine is protective, and may provide a new and useful prospective immune correlate of protection for vaccines based on T-helper type 1 (TH1) cells.
Journal ArticleDOI
Leishmaniasis: complexity at the host–pathogen interface
Paul M. Kaye,Phillip Scott +1 more
TL;DR: Recent evidence suggests that each host–pathogen combination evokes different solutions to the problems of parasite establishment, survival and persistence in Leishmania spp.
Journal ArticleDOI
A Review of the Geographic Distribution and Epidemiology of Leishmaniasis in the New World
TL;DR: The data summarized in this paper on parasite taxonomy and geographic distribution come from studies of greater than 1,000 New World Leishmania isolates identified by species-specific monoclonal antibodies using an indirect radioimmune binding assay and from scientific literature.